Search research articles
Contact Us
Filters
Showing results (81-90 of 97) with videos related to
Page
of 10
Sort By:
International Journal of Fertility
|
January 1, 1980
Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man
F Labrie, L Cusan, C Séguin, et al.
The Prostate
|
February 11, 1999
Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial
F Labrie, B Candas, A Dupont, et al.
Journal of Steroid Biochemistry
|
October 1, 1989
Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer
F Labrie, A Dupont, L Cusan, et al.
The Prostate
|
August 29, 2000
Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer
B Candas, L Cusan, J L Gomez, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale
|
December 1, 1993
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial
F Labrie, A Dupont, L Cusan, et al.
Advances in Experimental Medicine and Biology
|
January 1, 1979
Inhibitory effects of treatment with LHRH or its agonists on ovarian receptor levels and function
F Labrie, C Auclair, L Cusan, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale
|
December 1, 1993
Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen
F Labrie, A Dupont, R Suburu, et al.
Maturitas
|
October 1, 1991
Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women
A Dupont, P Dupont, L Cusan, et al.
Journal of Steroid Biochemistry
|
January 1, 1988
Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice
F Labrie, A Dupont, L Cusan, et al.
Urology
|
March 1, 1997
Neoadjuvant hormonal therapy: the Canadian experience
F Labrie, L Cusan, J L Gomez, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 97) with videos related to
Sort By:
Page
of 10
International Journal of Fertility
|
January 1, 1980
Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man
F Labrie, L Cusan, C Séguin, et al.
The Prostate
|
February 11, 1999
Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial
F Labrie, B Candas, A Dupont, et al.
Journal of Steroid Biochemistry
|
October 1, 1989
Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer
F Labrie, A Dupont, L Cusan, et al.
The Prostate
|
August 29, 2000
Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer
B Candas, L Cusan, J L Gomez, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale
|
December 1, 1993
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial
F Labrie, A Dupont, L Cusan, et al.
Advances in Experimental Medicine and Biology
|
January 1, 1979
Inhibitory effects of treatment with LHRH or its agonists on ovarian receptor levels and function
F Labrie, C Auclair, L Cusan, et al.
Clinical and Investigative Medicine. Medecine Clinique Et Experimentale
|
December 1, 1993
Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen
F Labrie, A Dupont, R Suburu, et al.
Maturitas
|
October 1, 1991
Comparative endocrinological and clinical effects of percutaneous estradiol and oral conjugated estrogens as replacement therapy in menopausal women
A Dupont, P Dupont, L Cusan, et al.
Journal of Steroid Biochemistry
|
January 1, 1988
Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice
F Labrie, A Dupont, L Cusan, et al.
Urology
|
March 1, 1997
Neoadjuvant hormonal therapy: the Canadian experience
F Labrie, L Cusan, J L Gomez, et al.
Page
of 10